Meta-analytical approach to evaluation of antihypertensive efficacy of Indapamide SR in hypertensive patients (results of open-label studies)

The paper presents a meta-analysis of open antihypertensive effectiveness trials of Indapamide SR (Arifon Retard, Servier Laboratories, France) in hypertensives. 24 Russian (n = 4952) and 4 foreign (n = 4634) trials were included in analysis. Russian trials show that Indapamide retard both as a monotherapy and a component of the combination therapy leads to a 17,8/14,0 % decrease of systolic/diastolic blood pressure that is a reduction for 29,2 (95 % ДИ 28,9-29,5)/12,3 (12,1-12,5) mmHg in patients with uncontrolled hypertension. Baseline blood pressure was the main predictor of its reduction, and the most significant reduction for 32,6 (95 % ДИ 25,5-39,6) was seen when the average baseline systolic blood pressure exceeded 170 mmHg. Antihypertensive efficacy of Indapamide retard was similar in Russian and foreign trials. However, incidence of therapy-related side effects was higher (5,9 %) in Russian trials than in foreign ones (3,3 %, p < 0,001). Therefore, meta-analysis based on the data of open Russian trials confirms the antihypertensive effectiveness of Indapamide retard and demonstrates the comparability of the results to those found in multicenter foreign studies.